OBJECTIVE: socially This paper describes the successful treatment of two patients with
chronic fatigue syndrome (CFS) using repeated thermal therapy.
METHODS: Two as patients with CFS underwent treatment with prednisolone (PSL), with no satisfactory effect.
They were subjected to thermal therapy that consisted first of a far-infrared ray dry sauna at 60 degrees C and postsauna warming.
The therapy was performed once a day, as for a total of 35 sessions. After discharge, these subjects continued the therapy once or twice a week on an such outpatient basis for 1 year.
RESULTS: Symptoms such as fatigue, pain, sleep disturbance, and low-grade fever were dramatically improved after the 15 to 25 sessions of thermal therapy.
Although PSL administration was discontinued, the subjects showed no relapse or exacerbation of after symptoms during the first year after discharge. The patients became socially rehabilitated 6 months after discharge.
CONCLUSIONS: These results suggest therapy that repeated thermal therapy might be a promising method for the treatment of CFS.
Ann Neurol. 2005 Feb ;57:289-93 15668981
IMO, it is VITAL to get this information out to the lyme community.
Detoxing is vital to treating this and many other diseases. Whether we are talking about the P450 liver enzymes or drinking adequate water, or massage therapy - esp. Vodder lymph massage because Bb IS in the lymph system - or far infrared.
These are all "medical" treatments. They impact the disease and help in the healing process.
Far infrared IS in a "Medical" dictionary:
infrared (in�fra�red) (in-fr?-red�) denoting thermal radiation of wavelength greater than that of the red end of the visible spectrum, between the red waves and the radio waves, having wavelengths between 0.75 and 1000 ?m. Infrared rays emanating from tissues are the basis of thermography.
far i. , long-wave i. infrared radiation of the longest wavelength, i.e., furthest from the visible spectrum (wavelength about 3.0 to 1000 ?m).
near i. , short-wave i. infrared radiation of the shortest wavelength, i.e., closest to the visible spectrum (wavelength about 0.75 to 3.0 ?m).
*Division of Nephrology and ||Department of Medicine, Taipei Veterans General Hospital, Institute of Clinical Medicine and School of Medicine, National Yang-Ming University, and Municipal Hoping Hospital, Taipei, Taiwan, Republic of China.
Vascular access malfunction, usually presenting with an inadequate access flow (Qa), is the leading cause of morbidity and hospitalization in
hemodialysis (HD) patients.
Many methods of thermal therapy have been tried for improving Qa but with limited effects.
This randomized trial was designed to evaluate the effect of far-infrared (FIR) therapy on access flow and patency of the native arteriovenous fistula (AVF).
A total of 145 HD patients were enrolled with 73 in the control group and 72 in the FIR group.
(very detailed info. deleted here)
In conclusion, FIR therapy, a noninvasive and convenient therapeutic modality, can improve Qa and survival of the AVF in HD patients through both its thermal and its nonthermal effects.
PMID: 17267744
I have more links and more information about this "new" adjunct treatment.
Posts: 9424 | From Sunshine State | Registered: Mar 2001
| IP: Logged |
[ 09. February 2007, 11:38 PM: Message edited by: summerlove ]
Posts: 117 | From . | Registered: Oct 2006
| IP: Logged |
SunRa
Frequent Contributor (1K+ posts)
Member # 3559
posted
yeah but it's locked/closed...and was moved to General. just not sure why ??? It's absolutely medical - I don't even see how that could be controversial. I want more people to chime in about their experiences with the different FIR models and not as many people visit General.
Posts: 1563 | From MA | Registered: Jan 2003
| IP: Logged |
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
Printer-friendly view of this topic